Are there any age restrictions for cosentyx treatment?

What are the age requirements for Cosentyx treatment?

Cosentyx (secukinumab) is a biologic medication used to treat several autoimmune diseases, including plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and Crohn's disease. According to the prescribing information [1], Cosentyx is approved for use in patients aged 6 years and older with plaque psoriasis.

Can children under 6 years old be treated with Cosentyx?

The US Food and Drug Administration (FDA) has approved Cosentyx for children as young as 6 years old, but it has not been studied in children under 6. The safety and efficacy of Cosentyx in this age group have not been established [1].

How about older adults: are there any age restrictions for Cosentyx treatment?

There are no specific age restrictions for Cosentyx treatment in older adults. However, patients aged 65 years and older may be more susceptible to infections and other complications, such as malignancies, associated with biologic therapy [2]. Additionally, patients with a history of malignancies or those with weakened immune systems may also require closer monitoring.

Are there any age-related considerations for treating patients with Cosentyx?

As with any medication, patients of all ages should be monitored for potential side effects, such as infections, allergic reactions, and liver damage. Older adults may be at higher risk for these complications and should be carefully monitored by their healthcare provider.

References

[1] Novartis Pharmaceuticals Corp. (2022). Cosentyx (secukinumab) Prescribing Information.

[2] European Medicines Agency. (2022). Cosentyx (secukinumab) European Medicines Agency.

DrugPatentWatch.com: For more information on Cosentyx patents and exclusivity periods, visit DrugPatentWatch.com [www.drugpatentwatch.com].

In the case of Secukinumab (Cosentyx), the patent for the US market expired in 2029.